BioCardia
Sunnyvale, California, United States · Biotechnology, Healthcare, Health Care
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic
Key facts
- Headquarters
- Sunnyvale, California, United States
- Employees
- 28
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (BCDA)
- Website
- biocardia.com
- Company page
Recent activity at BioCardia
- : SEC 8-K (8.01): On October 19, 2026, BioCardia, Inc. announced the FDA's acceptance of its De Novo Pre-Submission Package for the Helix Catheter marketing clearance. This event is significant as it represents a critical step in the FDA approval process, anticipating a substantive review meeting this quarter, which could impact BioCardia's product development timeline and market entry plans. The announcement is expected to enhance investor confidence and suggests a focus on advancing their innovative medical technologies. The press release is included as Exhibit 99.1 of the filing.
- : SEC 8-K (8.01): On October 7, 2026, BioCardia, Inc. announced the presentation of the CardiAMP HF II Trial design at the Heart Failure Society of America Annual Scientific Meeting. This event represents a significant milestone in advancing their cardiovascular treatment research. The trial aims to address heart failure, and the presentation is expected to draw interest from medical professionals and stakeholders in the healthcare sector. The timing of the announcement on the same day as the event underscores BioCardia's commitment to transparency and engagement with the scientific community.
- : SEC 8-K (8.01): On October 1, 2026, BioCardia, Inc. announced the completion of its revised Pre-Submission to the FDA Center for Devices and Radiological Health (CDRH) under the Q-Submission program. This submission pertains to the approval process for their Helix Catheter, which is intended for therapeutic and diagnostic agent delivery to the heart. The press release included in Exhibit 99.1 outlines the significance of this submission in advancing their medical device strategies, demonstrating BioCardia's commitment to innovation and compliance with regulatory standards. The event date is significant as it represents a key milestone in the company's journey towards regulatory approval and market entry.
- : SEC 8-K (8.01): On September 23, 2026, BioCardia, Inc. issued a press release providing an update on the timing of its FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission. This update is significant for stakeholders as it pertains to critical regulatory submissions relevant to the company's cardiovascular therapeutic development. The press release is attached as Exhibit 99.1 and may impact the company's operations and market perception moving forward.
- : SEC 8-K (8.01): On September 21, 2026, BioCardia, Inc. received confirmation from the NASDAQ Staff that it had regained compliance with the Minimum Bid Price Requirement, as the company’s common stock closed at $1.00 or greater for at least 10 consecutive business days. This follows a previous notification received on August 19, 2026, regarding its non-compliance due to the stock price falling below $1.00 for 30 consecutive business days. The resolution of this matter allows BioCardia to continue its listing on the Nasdaq Capital Market without any trading impact on its stock. This compliance reinstatement is critical for the company's ongoing market presence and investor confidence.
- : SEC 8-K (8.01): On September 10, 2026, BioCardia, Inc. announced that its President and CEO, Peter Altman, Ph.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place from September 14-16, 2026, at the Lotte New York Palace Hotel in New York City. This event is significant as it allows the company to showcase its developments to investors and industry professionals, which could lead to increased interest and potential investments. The attached press release (Exhibit 99.1) provides further details about the presentation and the conference agenda.
- : SEC 8-K (7.01): On August 24, 2026, BioCardia, Inc. issued a press release indicating that the FDA has confirmed the meeting minutes concerning the Helix Transendocardial Delivery Catheter. This confirmation supports BioCardia's follow-on De Novo pre-submission for approval. The significance of this event lies in its potential impact on advancing regulatory processes and facilitating access to the market for their innovative medical device. The press release has been included as Exhibit 99.1, which provides further details on the discussion and next steps.
- : SEC 8-K (3.01): On August 19, 2026, BioCardia, Inc. received a notice from Nasdaq regarding non-compliance with the Minimum Bid Price Requirement, as the company's stock price has been below $1.00 for the last 30 consecutive business days. The notice indicates that the company has until February 16, 2027, to regain compliance by achieving a closing bid price of $1.00 or more. This situation reflects a significant governance and operational challenge for the company, necessitating actions to enhance market performance. The implications of this notice could impact investor perception and funding opportunities for BioCardia.
- : SEC 8-K (7.01): On June 18, 2026, BioCardia, Inc. issued a press release detailing its letter to shareholders, which outlines the company's current business strategy, key priorities, and potential business development opportunities. This communication serves to inform investors and stakeholders about the company's direction and updates. Although this disclosure is part of a Regulation FD filing, it specifically aims to enhance transparency regarding BioCardia's operations and strategic vision. The press release is attached as Exhibit 99.1 to the filing.
- : SEC 8-K (8.01): On June 5, 2026, BioCardia, Inc. sold 3,509,604 shares at an average price of $1.279 through its 'At The Market' offering agreement with H.C. Wainwright & Co. This transaction was officially announced in a press release issued on June 8, 2026. The strategic implication of this sale indicates the Company’s efforts to raise capital while leveraging market conditions. The proceeds from the sale are intended to be used for general corporate purposes in line with the Company’s growth strategy.
BioCardia funding history
| Date | Round | Amount |
|---|---|---|
| Jan 2019 | Seed | $4.0M |
| Nov 2016 | Venture | $35.9M |
Leadership
- ALLAN TESSLER, Director
- SIMON STERTZER, Director
- THOMAS QUERTERMOUS, Director
- RICHARD JR, Director
- JAY MOYES, Director
- RICHARD KRASNO, Director
- FERNANDO FERNANDEZ, Director
- PETER ALTMAN, Executive Officer, Director, Promoter
- Farhan Shahab, Vice President
- PHIL PESTA, Executive Officer
- DAVID MCCLUNG, Executive Officer
- ERIC DUCKERS, Executive Officer
Verified email and direct lines for BioCardia’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
BioCardia files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
BioCardia in the news
- BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results - Yahoo Finance (Aug 12, 2026)
- BioCardia Confirms Timing and Provides Update on FDA Helix - GlobeNewswire (Sep 23, 2026)
- BioCardia’s CardiAMP Shows 179-Second Exercise Gain in Refractory Angina Trial - The Clinical Trial Vanguard (May 25, 2026)
- BioCardia, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance (Aug 12, 2026)
- BioCardia to Report Second Quarter 2026 Financial Results and Provide Corporate Update on August 12 Conference Call - Quiver Quantitative (Aug 05, 2026)
- BioCardia Reveals Plans to Request Meeting With FDA Regarding CardiAMP Heart Failure Cell Therapy - CGTLive® (Aug 05, 2025)
- BCDA Surges As BioCardia Wins Key FDA Trial Breakthrough - StocksToTrade (Jun 06, 2026)
- FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF - Yahoo Finance (Jun 05, 2026)
Companies similar to BioCardia
- BioLineRx Ltd · Biotechnology, Healthcare, Health Care, Therapeutics
- NLS Pharmaceutics Ltd · Biotechnology, Healthcare, Health Care, Therapeutics
- AIM ImmunoTech · Biotechnology, Healthcare, Health Care, Therapeutics
- Tempest Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- Ovid Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
About BioCardia: questions and answers
What does BioCardia do?
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic
Where is BioCardia headquartered?
BioCardia is headquartered in Sunnyvale, California, United States.
How many employees does BioCardia have?
BioCardia has about 28 employees.
Has BioCardia raised funding?
Yes. Fundz has recorded 2 funding events for BioCardia. The most recent, Seed of $4.0M, was in Jan 2019.
Who leads BioCardia?
Farhan Shahab is a Vice President at BioCardia.
What is the latest news on BioCardia?
On Oct 19, 2026, SEC 8-K (8.01): On October 19, 2026, BioCardia, Inc. announced the FDA's acceptance of its De Novo Pre-Submission Package for the Helix Catheter marketing clearance. This event is significant as it represents a critical step in the FDA approval process, anticipating a substantive review meeting this
Is BioCardia a public company?
Yes. BioCardia is publicly traded under the ticker BCDA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy